



# euroPLX

# Business Developer

Vol. 14 # 3 | March | 2018

## Mergers & Acquisitions Continue Strongly After Last Year's Restraint

\* Investment: **Debiopharm Group** invested in antibiotic development with the acquisition of a minority stake in **ABAC Therapeutics Inc.** This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the synergy between the group companies in the fight against the worrying emergence of antibiotic resistance. 15 Feb 2018 ([www.debiopharm.com](http://www.debiopharm.com))

\* Acquisition and name change: **DanDrit Biotech USA, Inc.** finalized its acquisition of **Enochian Biopharma Inc.** and is in the process of changing its name to **Enochian BioSciences, Inc.** 23 Feb 2018 ([enochianbio.com](http://enochianbio.com))

\* Acquisition: **Mallinckrodt plc** closed the acquisition of **Sucampo Pharmaceuticals, Inc.**, a global biopharmaceutical company, including its commercial and development assets. The acquired assets include **AMITIZA®** (lubiprostone), a product in the branded constipation market, **RESCULA®** (unoprostone isopropyl ophthalmic solution) 0.15%, for ocular hypertension and open-angle glaucoma, and two Phase 3 candidates. 13 Feb 2018 ([www.mallinckrodt.com](http://www.mallinckrodt.com))

\* Co-Development: **Eisai Co., Ltd.** and **Merck**, known as **MSD** outside the United States and Canada,

have agreed upon a strategic collaboration for the worldwide co-development and co-commer-

for the treatment of patients with renal cell carcinoma (RCC) who have failed previous therapy. 7

prostate cancer. Available in 67 countries, **Eligard** is currently marketed in the United States, Australia and New Zealand by **Tolmar**. 19 Feb 2018 ([www.mundipharma.co.uk](http://www.mundipharma.co.uk))

\* Distribution: **Noventure** and **Laboratorios Salvat, S.A.** have entered into an agreement in which **Salvat** will distribute **Noventure's** nasal mucoprotection product in Spain and Portugal. The product contains a mucomimetic agent that forms a protective barrier over the nasal epithelial mucosa. This is the first in a series of agreements to partner this innovative product around the world. The product will be available as a solution for intranasal application with an anticipated launch in April 2018. 21 Feb 2018 ([noventure.com](http://noventure.com))

\* Acquisition: **PCI Pharma Services** completed the acquisition of **Melbourne**, Australia-based **Pharmaceutical Packaging Professionals**, a leading provider of clinical trial manufacturing, packaging, storage and distribution services. 1 Mar 2018 ([/pciservices.com](http://pciservices.com))

\* No Acquisition: **PDL BioPharma, Inc.** officially announced it will no longer pursue its proposed acquisition of **Neos Therapeutics, Inc.** According to company sources they were „unable to agree on

### Advertisement - Position Offered

#### Medochemie: Out-Licensing Agent for Germany

**Medochemie Ltd**, a generic pharmaceutical company based in Cyprus, is looking for an out-licensing agent (individual) based in Germany, with at least 5 years of pharmaceutical licensing experience and good knowledge of the German pharmaceutical market, to act as the company's local agent. Remuneration will be solely based on commission.

For more details please contact us by email at [andreas.loizou@medochemie.com](mailto:andreas.loizou@medochemie.com) - or discuss this opportunity with us at euroPLX 67 Noordwijk

This is a free service to a euroPLX Community Member.

### Advertisement - Position Offered

#### DSM Sinochem Pharmaceuticals: Licensing & Sales Manager

To further strengthen its Out-Licensing activities, **DSM Sinochem Pharmaceuticals Netherlands** has the following open position in its business unit drug products: Licensing & Sales Manager

Detailed position profile and information on application process is available at LinkedIn profile of "DSM Sinochem Pharmaceuticals".

This is a free service to a euroPLX Community Member.

cialization of **LENVIMA®** (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by **Eisai**. Under the agreement, **Eisai** and **Merck** will develop and commercialize **LENVIMA** jointly, both as monotherapy and in combination with **Merck's** anti-PD-1 therapy, **KEYTRUDA®** (pembrolizumab). **LENVIMA** is currently approved as monotherapy for use in the treatment of thyroid cancer, as well as in combination with everolimus

Mar 2018 ([www.merck.com](http://www.merck.com))

\* Acquisition: **Mundipharma** acquired the specialist pharmaceutical company, **Tolmar Australia Pty Limited**, including exclusive distribution rights for the oncology medication **Eligard** (leuprorelin acetate) in Australia and New Zealand. The acquisition includes the oncology medications **Eligard** and **Bi-Eligard** - established hormonal therapies indicated for the palliative treatment of advanced

terms that were in the best interest of our shareholders." 20 Feb 2018 ([www.pdl.com](http://www.pdl.com))

\* Acquisition: **Pinnacle Dermatology** acquired the **Van Dam Dermatology and Laser Center**, located in Barrington, Illinois. 15 Mar 2018 ([www.pinnacledermar.com](http://www.pinnacledermar.com))

\* Acquisition: **Pivot Pharmaceuticals Inc.**, an emerging biotechnology company engaged in the development of therapeutics to meet unmet medical needs in women's health, has acquired **ThruDermic, LLC**, a privately held North Carolina company. 6 Mar 2018 ([www.pivotpharma.com/](http://www.pivotpharma.com/))

\* Acquisition: **Sanofi** has completed the acquisition of **Bioverativ Inc.** for \$105 per share in cash. 9 Mar 2018 ([www.sanofi.com](http://www.sanofi.com))

\* Acquisition: **Seattle Genetics, Inc.** has completed its previously announced acquisition of **Cascadian Therapeutics, Inc.** The most advanced program in Cascadian Therapeutics' pipeline

is tucatinib, an investigational oral tyrosine kinase inhibitor (TKI) that is highly selective for HER2, a growth factor receptor that is overexpressed in multiple cancers, including breast, colorectal, ovarian and gastric. Tucatinib is currently being evaluated in a randomized global pivotal trial. 9 Mar 2018 ([www.seagen.com](http://www.seagen.com))

\* Licensing: A subsidiary of **Valeant Pharmaceuticals International, Inc.** has entered into an exclusive license agreement with **Kaken Pharmaceutical Co., Ltd.**, to develop and commercialize products containing a new chemical entity, KP-470, which is an investigational compound for the topical treatment of psoriasis. If approved, KP-470 will represent a novel drug with an alternate mechanism of action in the topical treatment of the disease. 27 Feb 2018 ([www.valeant.com](http://www.valeant.com))

## BD People on the Move

\* AGC Biologics: **Axel Schleyer** has been appointed as Senior

Vice President of Business Development, North America, and Christoph Winterhalter as Senior Vice President of Business Development, Europe. (Press Release 13 Mar 2013)

\* Aurinia Pharmaceuticals Inc.: **Joseph P. Hagan** has been added to the company's board of directors, overlooking the company's Commercial and Business Development (Press Release 8 Feb 2018)

\* Biofabri S.L.: **Sergi Moreno Aymami** has been appointed as Manager Business Development and will attend euroPLX 67 Noordwijk. (Pers Comm 13 Feb 2018)

\* BioStem Technologies, Inc.: **Dr. Felix Amon** has been hired as consultant for Pharmaceutical Business Development. (Press Release 13 Mar 2018)

\* CytRx Corp.: **Eric L. Curtis** has been added to its corporate development team to pursue new strategic partnering opportunities

with large pharma and biotech companies. (Press Release 1 March 2018)

\* Gebro Pharma: **Helena Arumí**, who has been Business Development Manager at Laboratorios Gebro Pharma, S.A., left the company. (Pers Comm 8 Feb 2018)

\* Marapharm Ventures Inc.: **Corey Klassen** has been appointed as Vice President of Corporate Development. (Press Release 8 Mar 2018)

\* PCI Pharma Services: **Robert Gibbs** has been appointed as Business Development Manager for Laboratory Services, and Laura Zurlinden to the role of director of Business Development – West Coast Commercial Packaging. (Press Release 8/16 Feb 2018)

\* Retrophin: **Casey Logan** has been appointed as Vice President, Corporate Development. (Press Release 5 Mar 2018)

\* Veritas Pharma Inc.: **Justin Kausel** has been appointed as Director

# Insanely Effective Pharma Partnering

euroPLX is the world's most often held partnering conference for the pharma and biopharma industries.

Because of results delivered. Year-round.

Join the 67th International Partnering Conference for Pharma Business Development\*

\*euroPLX 67 Noordwijk (The Netherlands)

June 11 + 12, 2018, Grand Hotel Huis ter Duin, Noordwijk

Seeking and offering business opportunities in patented and generic (incl. biosimilars), prescription and OTC drugs, medical devices, and nutraceuticals - development, licensing, marketing, promotion, and distribution...

Each euroPLX Conference's actual collaboration interests are summarised and displayed on [www.europlx.com](http://www.europlx.com) as an hourly updated **Dynamic Partnering Focus**, as soon as sufficient data are submitted by registrants.

 **euroPLX**  
by RauCon

[www.europlx.com](http://www.europlx.com)  
[meetyou@europlx.com](mailto:meetyou@europlx.com)  
ph. ++49 (6221) 426296-0

The Original since 1995.  
Often copied. Never equaled.

Register online: [www.europlx.com](http://www.europlx.com)

